Wird geladen...
Risk stratification of castration-resistant prostate cancer patients treated with cabazitaxel
Patient characteristics before administering the first cycle of cabazitaxel for metastatic castration-resistant prostate cancer (mCRPC) were collected to assess prognostic factors for overall survival (OS). Multivariate analysis revealed that prostate-specific antigen (PSA) ≥100 ng/ml prior to cabaz...
Gespeichert in:
| Veröffentlicht in: | Mol Clin Oncol |
|---|---|
| Hauptverfasser: | , , , |
| Format: | Artigo |
| Sprache: | Inglês |
| Veröffentlicht: |
D.A. Spandidos
2018
|
| Schlagworte: | |
| Online Zugang: | https://ncbi.nlm.nih.gov/pmc/articles/PMC6256178/ https://ncbi.nlm.nih.gov/pubmed/30546902 https://ncbi.nlm.nih.govhttp://dx.doi.org/10.3892/mco.2018.1724 |
| Tags: |
Tag hinzufügen
Keine Tags, Fügen Sie den ersten Tag hinzu!
|